Tech Company Financing Transactions

Alucent Biomedical Funding Round

Fresenius Medical Care and private investors participated in a $35 million Series B funding round for Alucent Biomedical. The round was announced on 10/6/2020.

Transaction Overview

Company Name
Alucent Biomedical
Announced On
10/6/2020
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series B
Investors

Fresenius Medical Care (Lead Investor) (Al Wiegman)

Proceeds Purpose
The funding will be used to support the completion of two clinical trials: the currently enrolling ACTIVATE I first-in-human trial; and the larger ACTIVATE II trial to evaluate the safety and efficacy of the company's revolutionary Alucent Natural Vascular Scaffolding (AlucentNVS) Vessel Restoration System with Photoactivated Linking, the company's intended commercial product.

Company Information

Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
675 Arapeen Dr. 102
Salt Lake City, UT 84108
USA
Phone
(385) 722-2300
Website
www.alucentmedical.com
Email Address
Not Recorded
Overview
Alucent Biomedical is a privately held biomedical company focused on our vision to transform the way vascular disease is treated. We are focused on using advanced technology to harness the body's own natural physiologic processes and structures. Alucent Biomedical was founded by the Avera Research Institute of Avera Health and became a standalone company in 2017.
Profile
Alucent Biomedical LinkedIn Company Profile
Social Media
Alucent Biomedical Company Twitter Account
Company News
Alucent Biomedical News
Facebook
Alucent Biomedical on Facebook
YouTube
Alucent Biomedical on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Myles Greenberg
  Myles Greenberg LinkedIn Profile  Myles Greenberg Twitter Account  Myles Greenberg News  Myles Greenberg on Facebook
Vice President
Hank Hauser
  Hank Hauser LinkedIn Profile  Hank Hauser Twitter Account  Hank Hauser News  Hank Hauser on Facebook
Vice President
Katalin Kauser
  Katalin Kauser LinkedIn Profile  Katalin Kauser Twitter Account  Katalin Kauser News  Katalin Kauser on Facebook
Vice President
Kevin Warner
  Kevin Warner LinkedIn Profile  Kevin Warner Twitter Account  Kevin Warner News  Kevin Warner on Facebook
VP - Finance
Scott Mayfield
  Scott Mayfield LinkedIn Profile  Scott Mayfield Twitter Account  Scott Mayfield News  Scott Mayfield on Facebook
VP - R & D
Steve Tyler
  Steve Tyler LinkedIn Profile  Steve Tyler Twitter Account  Steve Tyler News  Steve Tyler on Facebook
VP - Regulatory Affairs
Bruce Krattenmaker
  Bruce Krattenmaker LinkedIn Profile  Bruce Krattenmaker Twitter Account  Bruce Krattenmaker News  Bruce Krattenmaker on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/6/2020: Strike Graph venture capital transaction
Next: 10/6/2020: Uni Cards venture capital transaction

 

Share this article

 

About Our VC Transactions Data

Our team works diligently to record funding rounds that are announced publicly. VC investment data records reported here come from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.